Massachusetts Society of Clinical Oncologists - FDA Approves romiplostim (NPlate) for pediatric patients with ITP

"The voice for cancer physicians and their patients in Massachusetts."

Home
Resources
FDA Approvals
FDA Approves romiplostim (NPlate) for pediatric patients with ITP

FDA Approves romiplostim (NPlate) for pediatric patients with ITP

14 Jan 2019 3:08 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved romiplostim (Nplate; Amgen) for pediatric patients 1 year of age and older with immune thrombocytopenia (ITP) for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org